- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03033641
FIND CAN Trial: "CF-172" (FIND CAN)
Feasibility of the CARTOFINDER™ 4D LAT Algorithm to Identify Ablation Target in Subjects With Atrial Fibrillation (FIND CAN Trial: "CF-172")
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ontario
-
Newmarket, Ontario, Canada, L3Y 2P9
- Southlake Regional Health Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Subjects must meet the following inclusion criteria:
- Age > 18 years.
- Patients who have signed the Patient Informed Consent Form (ICF)
Scheduled to undergo a clinically-indicated catheter ablation procedure for treatment of persistent atrial fibrillation (defined as continuous atrial fibrillation that is sustained beyond seven consecutive days).
3.1. Drug-refractory atrial fibrillation. (failed 1 or more class I or III antiarrhythmic drugs) and demonstrating Persistent AF (requiring drugs or electrical shock to terminate)
- Able and willing to comply with all pre-, post-, and follow-up testing and requirements (e.g. patients not confined by a court ruling)
Exclusion Criteria:
Subject who meet any of the following exclusion criteria are not eligible for enrollment.
- Paroxysmal Atrial Fibrillation
- Continuous AF > 12 months (1 Year) (Longstanding Persistent AF) 2.1. Subjects previously diagnosed as Long Standing Persistent (LSP) but have demonstrated the ability to maintain Normal Sinus Rhythm for >30 days after cardioversion and have not been in AF greater than 1 year at the time of the procedure remain eligible for inclusion.
- Previous ablation procedure for AF (previous ablation for the treatment of Flutter is acceptable)
- Patients with a left atrial size >55 mm (echocardiography, parasternal long axis view).
- Inability to restore sinus rhythm for 30 seconds or longer in the opinion of the investigator.
- Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment in this study.
- Atrial arrhythmia patients with structural atrial disease such as a prior history of atriotomy from prior atrial surgery, presence of an atrial septal defect, and/or presence of an atrial septal closure patch.
- History of or current blood clotting or bleeding abnormalities, contraindication to systemic anticoagulation (i.e., heparin, warfarin, dabigatran, or a direct thrombin inhibitor), significant pulmonary disease, unstable angina, uncontrolled heart failure, acute illness or systemic infection, or any other disease or malfunction that would preclude treatment in the opinion of the investigator.
- Enrollment in a study evaluating another device or drug.
- A complex arrhythmia secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause.
- Patients with a prosthetic mitral valve or any mechanical valve
- Any cardiac surgery within the past 60 days (2 months) (includes PCI) (bypass within the past year)
- Subjects that have ever undergone valvular cardiac surgical procedure (ie, ventriculotomy, atriotomy, and valve repair or replacement and presence of a prosthetic valve)
- Prior ICD or pacemaker implanted
- Presence of intramural thrombus, tumor or other abnormality that precludes catheter introduction or manipulation.
- Presence of a condition that precludes vascular access.
- Subject has a contra-indication to any of the devices used in the study per the IFU
- Women of child bearing potential who are pregnant, lactating, or planning to become pregnant during the course of the trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ablation procedure
|
All enrolled subjects who have ablation targets identified will undergo CARTOFINDER guided ablation (CFGA) followed by PVI.
Subjects will be followed per the protocol schedule.
Subjects who have no ablation target identified on the baseline CARTOFINDER map will undergo ablation per the institution's standard of care and be followed for 7 days for safety monitoring, then exit from the study.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate mapping characteristics
Time Frame: Intraoperative
|
Explore characteristics of ablation targets identified by the CARTOFINDER 4D LAT Algorithm
|
Intraoperative
|
Evaluate acute safety of freedom from procedure-related primary adverse events
Time Frame: Within 7 days
|
Evaluate acute safety of freedom from procedure-related primary adverse events occurring within 7 days of ablation procedure
|
Within 7 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate atrial fibrillation (AF) termination
Time Frame: Perioperative
|
Evaluate the AF termination to Normal Sinus Rhythm (NSR) or an Atrial Tachycardia (AT) after CARTOFINDER™ Guided Ablation (CFGA) of identified ablation target and after PVI
|
Perioperative
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BWI CF-172
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Persistent Atrial Fibrillation
-
Ablacon, Inc.CompletedArrhythmias, Cardiac | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationGermany
-
University of LuebeckIHF GmbH - Institut für HerzinfarktforschungRecruitingPersistent or Long-standing Persistent Atrial FibrillationGermany
-
AtriCure, Inc.Active, not recruitingPersistent Atrial Fibrillation | Atrial Fibrillation (AF) | Longstanding Persistent Atrial FibrillationUnited States
-
Xinhua Hospital, Shanghai Jiao Tong University...RecruitingPersistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationChina
-
University Medical Centre LjubljanaWithdrawnPersistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationSlovenia
-
AtriCure, Inc.CompletedPersistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationUnited States
-
Medtronic Bakken Research CenterTerminatedLongstanding Persistent Atrial FibrillationSpain, Germany, Israel, Italy
-
St. George's Hospital, LondonRecruitingAtrial Fibrillation | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial ArrhythmiaUnited Kingdom
-
Barts & The London NHS TrustAtriCure, Inc.Not yet recruitingAtrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial Arrhythmia | Atrium; FibrillationUnited Kingdom
-
Medtronic Cardiac SurgeryRecruitingPersistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationUnited States
Clinical Trials on Ablation procedure
-
AtriCure, Inc.CompletedAtrial FibrillationUnited States, Netherlands, Belgium
-
Boston Scientific CorporationCompletedParoxysmal Atrial FibrillationSpain, Germany, Italy
-
Boston Scientific CorporationCompletedParoxysmal Atrial FibrillationUnited Kingdom, Spain, France, Germany
-
Heart Rhythm Clinical and Research Solutions, LLCAttune MedicalNot yet recruiting
-
Heart Rhythm Clinical and Research Solutions, LLCBiosense Webster, Inc.Recruiting
-
Medtronic Cardiac Rhythm and Heart FailureMedtronicCompletedParoxysmal Atrial FibrillationDenmark, Netherlands, Germany, Switzerland
-
University of California, San FranciscoCompletedNeurocognitive DysfunctionUnited States, Canada
-
Cardiovascular Innovation and Research InstituteValley View HospitalRecruitingCoronary Artery Disease | Atrial Fibrillation (AF)United States
-
Vektor MedicalExperien GroupCompletedAtrial Fibrillation | Ventricular Fibrillation | Ventricular Tachycardia | Ventricular Arrythmia | Cardiac Arrhythmia | Premature Ventricular Complexes Multiple | Premature Atrial Complex | Atrioventricular Reentrant TachycardiaUnited States
-
University of AarhusCompletedAtrial Fibrillation | Burden of Atrial FibrillationDenmark